Answers are grounded in this paper and cite their sources.
Review highlights evidence gaps for daratumumab quadruplet induction and stem cell transplant in adults aged 70 and older, indicating limited trial generalizability.
The addition of daratumumab to triplet induction regimens has significantly improved depth of response and progression-free survival (PFS) in newly diagnosed multiple myeloma (MM), as demonstrated in the GRIFFIN and PERSEUS trials, both of which evaluated daratumumab, bortezomib, lenalidomide, and dexamethasone (D-VRD) induction followed by autologous hematopoietic cell transplantation (autoHCT) [ 1 , 2 ]. However, both trials excluded patients over age 70, limiting the generalizability of these findings to older adults, a population in which MM is commonly diagnosed [ 3 ]. Although limited real-world data suggest a benefit of D-VRD induction [ 4 ] over triplets, evidence in older patients is lacking.
No takes yet. Share an insight, caveat, or question.
Pasvolsky et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: